Vitrakvi
Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer
April 21, 2020Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …
Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation
July 30, 2019Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …
FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi
November 27, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
